» Articles » PMID: 25788973

PET-specific Parameters and Radiotracers in Theoretical Tumour Modelling

Overview
Publisher Hindawi
Date 2015 Mar 20
PMID 25788973
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The innovation of computational techniques serves as an important step toward optimized, patient-specific management of cancer. In particular, in silico simulation of tumour growth and treatment response may eventually yield accurate information on disease progression, enhance the quality of cancer treatment, and explain why certain therapies are effective where others are not. In silico modelling is demonstrated to considerably benefit from information obtainable with PET and PET/CT. In particular, models have successfully integrated tumour glucose metabolism, cell proliferation, and cell oxygenation from multiple tracers in order to simulate tumour behaviour. With the development of novel radiotracers to image additional tumour phenomena, such as pH and gene expression, the value of PET and PET/CT data for use in tumour models will continue to grow. In this work, the use of PET and PET/CT information in in silico tumour models is reviewed. The various parameters that can be obtained using PET and PET/CT are detailed, as well as the radiotracers that may be used for this purpose, their utility, and limitations. The biophysical measures used to quantify PET and PET/CT data are also described. Finally, a list of in silico models that incorporate PET and/or PET/CT data is provided and reviewed.

Citing Articles

Design, Synthesis, and Biological Evaluation of Small-Molecule-Based Radioligands with Improved Pharmacokinetic Properties for Imaging of Programmed Death Ligand 1.

Krutzek F, Donat C, Ullrich M, Stadlbauer S J Med Chem. 2023; 66(23):15894-15915.

PMID: 38038981 PMC: 10726354. DOI: 10.1021/acs.jmedchem.3c01355.


Exploring Hydrophilic PD-L1 Radiotracers Utilizing Phosphonic Acids: Insights into Unforeseen Pharmacokinetics.

Krutzek F, Donat C, Stadlbauer S Int J Mol Sci. 2023; 24(20).

PMID: 37894769 PMC: 10606431. DOI: 10.3390/ijms242015088.


Design and Biological Evaluation of Small-Molecule PET-Tracers for Imaging of Programmed Death Ligand 1.

Krutzek F, Donat C, Ullrich M, Zarschler K, Ludik M, Feldmann A Cancers (Basel). 2023; 15(9).

PMID: 37174103 PMC: 10177516. DOI: 10.3390/cancers15092638.


Impact of segmentation and discretization on radiomic features in Ga-DOTA-TOC PET/CT images of neuroendocrine tumor.

Liberini V, De Santi B, Rampado O, Gallio E, Dionisi B, Ceci F EJNMMI Phys. 2021; 8(1):21.

PMID: 33638729 PMC: 7914329. DOI: 10.1186/s40658-021-00367-6.


Radiomic detection of microscopic tumorous lesions in small animal liver SPECT imaging.

Veres D, Mathe D, Hegedus N, Horvath I, Kiss F, Taba G EJNMMI Res. 2019; 9(1):67.

PMID: 31346827 PMC: 6658620. DOI: 10.1186/s13550-019-0532-7.


References
1.
Pfannenberg A, Aschoff P, Brechtel K, Muller M, Bares R, Paulsen F . Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2006; 34(1):36-44. DOI: 10.1007/s00259-006-0186-3. View

2.
Smallbone K, Gatenby R, Maini P . Mathematical modelling of tumour acidity. J Theor Biol. 2008; 255(1):106-12. DOI: 10.1016/j.jtbi.2008.08.002. View

3.
Zhang X, Lin Y, Gillies R . Tumor pH and its measurement. J Nucl Med. 2010; 51(8):1167-70. PMC: 4351768. DOI: 10.2967/jnumed.109.068981. View

4.
Watabe H, Ikoma Y, Kimura Y, Naganawa M, Shidahara M . PET kinetic analysis--compartmental model. Ann Nucl Med. 2007; 20(9):583-8. DOI: 10.1007/BF02984655. View

5.
Holland J, Lewis J, Dehdashti F . Assessing tumor hypoxia by positron emission tomography with Cu-ATSM. Q J Nucl Med Mol Imaging. 2009; 53(2):193-200. PMC: 4418497. View